Skip to main content
Fig. 5 | Alzheimer's Research & Therapy

Fig. 5

From: Novel botanical drug DA-9803 prevents deficits in Alzheimer’s mouse models

Fig. 5

IBA1 and GFAP immunoreactivity after treatment with DA-9803 and vehicle. ad Fluorescent images of GFAP-positive astrocytes (a), IBA1-positive microglia (b), methoxy-XO4-labeled plaques (c), and colocalization of GFAP, IBA1, and methoxy-XO4 (d) in APP/PS1 mice treated with vehicle compound. eh Fluorescent microscope images of GFAP-positive astrocytes (e), IBA1-positive microglia (f), methoxy-XO4-labeled plaques (g), and colocalization of GFAP, IBA1, and methoxy-XO4 (h) in APP/PS1 mice treated daily with 100 mg/kg DA-9803. Scale bar, 20 μm. i Average number of astrocytes in close proximity (plaque) and away from plaques (no plaque) in a field of view across conditions. j Average number of microglia in close proximity (plaque) and away from plaques (no plaque) in a field of view across conditions. k, l High-magnification fluorescent images of GFAP-positive astrocytes treated with vehicle (k) and DA-9803 (l). m Astrocyte process length across conditions. n Astrocyte cell body diameter across conditions. o, p High magnification fluorescent images of IBA1-positive microglia treated with vehicle (o) and DA-9803 (p). q Microglial process length across conditions. r Microglial cell body diameter across conditions. Scale bar, 10 μm. Mean ± SEM. *p < 0.05, ***p < 0.001. n.s. not significant, GFAP glial fibrillary acidic protein

Back to article page